Appeals court weighs nationwide restrictions on abortion pill access

What This is

• A three-judge panel on the 5th U.S. Circuit Court of Appeals heard arguments in Louisiana v. FDA over rules for the abortion pill mifepristone.
• Louisiana is challenging FDA policies expanded during the COVID-19 pandemic and finalized in 2023 that allow mifepristone to be prescribed through telehealth and dispensed by pharmacies or mail, seeking restrictions that could reduce cross-state access to medication abortion.
• The Justice Department and the FDA argue the plaintiffs may lack standing, meaning they may not have the legal right to bring the case.
• The FDA is separately reviewing its mifepristone rules while the court case moves forward.
• Providers say that if mifepristone access is tightened, some may rely more on misoprostol alone for medication abortions.
• Other mifepristone lawsuits are also active, including a case by Texas and Florida attorneys general that a judge paused while the FDA completes its review.

Why This Matters

• The case could reshape how much power federal health regulators have versus states in setting rules that affect care across state lines.
• Telehealth rules for abortion pills have become a key way people get abortions after Roe was overturned, so changes could quickly alter access even without new laws.
• The outcome could affect how courts treat “standing,” which limits who can sue to change nationwide health rules.
• The fight also signals how much future FDA leadership and enforcement choices, not just elections and legislatures, can change reproductive health care.